pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›tivozanib
drug · small molecule
save

tivozanib

Phase 2updated 3mo ago
by Kyowa Kirin Co Ltd🔗 ChEMBL
Phase 2
community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for renal cell carcinoma and neoplasm and 10 investigational indications.

indications

indications
Diabetic Macular Edema

targets

Platelet-derived growth factor receptor betaVascular endothelial growth factor receptorMast/stem cell growth factor receptor Kit

all catalysts(0)

nothing on the calendar yet

Trials studying tivozanib

  • phase2Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Typesrecruitingn=29
  • phase2Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinomarecruitingn=48
  • phase3Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinomaactive not recruitingn=343
  • phase3A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)completedn=350
  • phase2A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinomaterminatedn=27

News(1)

  • Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
    Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.
    onclive · 3mo ago
generic
tivozanib
MOA
Platelet-derived growth factor receptor beta inhibitor; Vascular endothelial growth factor receptor inhibitor; Stem cell growth factor receptor inhibitor
indication
Wet (Neovascular / Exudative) Macular Degeneration
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 38m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?